251
Views
7
CrossRef citations to date
0
Altmetric
Original Article

Outcome of Multiple Implants and Dissociation of Fluocinolone Acetonide Intravitreal Implant (Retisert) in a Series of 187 Consecutive Implants

, MD, , MD, , MD, , MBBS, MPH, , MD, , BA & , MD, FACS, FACR show all
Pages 425-429 | Received 07 Aug 2014, Accepted 07 Nov 2014, Published online: 26 Dec 2014

References

  • Brumm MV, Nguyen QD. Fluocinolone acetonide intravitreal sustained release device—a new addition to the armamentarium of uveitic management. Int J Nanomed. 2007;2:55–64
  • Lim LL, Smith JR, Rosenbaum JT. Retisert (Bausch & Lomb/Control Delivery Systems). Curr Opin Invest Drugs. 2005;6:1159–1167
  • Jaffe GJ, Martin D, Callanan D, et al. Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study. Ophthalmology. 2006;113:1020–1027
  • Khalifa Y, Loh AR, Acharya NR. Fluocinolone acetonide intravitreal implants in Vogt-Koyanagi-Harada disease. Ocul Immunol Inflamm. 2009;17:431–433
  • Mahajan VB, Gehrs KM, Goldstein DA, et al. Management of sympathetic ophthalmia with the fluocinolone acetonide implant. Ophthalmology. 2009;116:552–557 e551
  • Patel CC, Mandava N, Oliver SC, et al. Treatment of intractable posterior uveitis in pediatric patients with the fluocinolone acetonide intravitreal implant (Retisert). Retina. 2012;32:537–542
  • Park UC, Kim SJ, Yu HG. Cytomegalovirus endotheliitis after fluocinolone acetonide (Retisert) implant in a patient with Behcet uveitis. Ocul Immunol Inflamm. 2011;19:282–283
  • Rofagha S, Prechanond T, Stewart JM. Late spontaneous dissociation of a fluocinolone acetonide implant (Retisert). Ocul Immunol Inflamm. 2013;21:77–78
  • Jaffe GJ. Reimplantation of a fluocinolone acetonide sustained drug delivery implant for chronic uveitis. Am J Ophthalmol. 2008;145:667–675
  • Allen RC, Suhler EB, Flaxel CJ, et al. Long-term follow-up of patients treated with multiple fluocinolone acetonide implants for noninfectious uveitis. J Ophthalmic Inflamm Infect. 2012;2:177–182
  • Jabs DA, Nussenblatt RB, Rosenbaum JT, et al. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol. 2005;140:509–516
  • Taban M, Lowder CY, Kaiser PK. Outcome of fluocinolone acetonide implant (Retisert) reimplantation for chronic noninfectious posterior uveitis. Retina. 2008;28:1280–1288
  • Yeh S, Cebulla CM, Witherspoon SR, et al. Management of fluocinolone implant dissociation during implant exchange. Arch Ophthalmol. 2009;127:1218–1221
  • Wan W, Stewart JM. Use of a high infusion rate to prevent posterior dislocation of fluocinolone acetonide implant during surgical removal. Ocul Immunol Inflamm. 2011;19:214–215
  • Nicholson BP, Singh RP, Sears JE, et al. Evaluation of fluocinolone acetonide sustained release implant (Retisert) dissociation during implant removal and exchange surgery. Am J Ophthalmol. 2012;154:969–973 e961
  • Jaffe GJ, McCallum RM, Branchaud B, et al. Long-term follow-up results of a pilot trial of a fluocinolone acetonide implant to treat posterior uveitis. Ophthalmology. 2005;112:1192–1198
  • Oh EK, Lee EK, Yu HG. Long-term results of fluocinolone acetonide intravitreal implant in Behcet intractable posterior uveitis. Can J Ophthalmol. 2014;49:273–278
  • Multicenter Uveitis Steroid Treatment Trial Research G, Kempen JH, Altaweel MM, Holbrook et al. The multicenter uveitis steroid treatment trial: rationale, design, and baseline characteristics. Am J Ophthalmol. 2010;149:550–561 e510
  • Jabs DA, Rosenbaum JT, Foster CS, et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol. 2000;130:492–513
  • Jaffe GJ, Ben-Nun J, Guo H, et al. Fluocinolone acetonide sustained drug delivery device to treat severe uveitis. Ophthalmology. 2000;107:2024–2033

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.